BNET Industries
AMAG Pharmaceuticals Inc. (AMAG) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $2.5M
- Profit
- Dec 31 2007
- ($33.8M)
- Market Cap
- Aug 27 2008
- $663.0M
Latest News and Analysis
AMAG Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript
AMAG Pharmaceuticals Inc. AMAG Q2 2008 Earnings Call
AMAG Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript
AMAG Pharmaceuticals Inc. AMAG Q1 2008 Earnings Call
AMAG Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript
AMAG Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript
Additional Resources
AMAG Pharmaceuticals, Inc. to Present at the Canaccord Adams 28th Annual Global Growth Conference
CAMBRIDGE, Mass. -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and Chief Executive Officer, will present an overview of the Company at the Canaccord Adams 28th Annual Global Growth Conference on Thursday, August 14 at 3:00 p.m. ET. The conference is being held August...
AMAG Pharmaceuticals, Inc. Reports Financial Results for the Quarter Ended June 30, 2008
CAMBRIDGE, Mass. -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the...
AMAG Pharmaceuticals, Inc. to Present at the Jefferies 2nd Annual Healthcare Conference
CAMBRIDGE, Mass. -- In first graph, first sentence of release, the date should read: Wednesday, June 25 (sted Thursday June, 25). The corrected release reads: AMAG PHARMACEUTICALS, INC. TO PRESENT AT THE JEFFERIES 2ND ANNUAL HEALTHCARE CONFERENCE AMAG Pharmaceuticals, Inc. (NASDAQ:...
Mergent, Inc. Announces Quarterly Rebalancing of HealthShares™ Indexes
NEW YORK, June 17 /PRNewswire/ -- Mergent, Inc., administrator for the HealthSharesTM Indexes, a series of 20 underlying indexes for the HealthSharesTM Exchange Traded Funds, today announced the quarterly rebalancing of the Indexes. The following securities will be added and deleted in the Indexes effective before...
AMAG Pharmaceuticals, Inc. Announces Presentation of Positive Results from Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement Therapy in Kidney Transplant Recipients at the American Transplant Congress
CAMBRIDGE, Mass. -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today announced positive results from pooled data...
StayinFront, Inc. and AMAG Pharmaceuticals, Inc. Sign Agreement for Customer Relationship Management Application
StayinFront, Inc., a global provider ofenterprise-wide customer relationship management CRM applications,decision support tools, data services and eBusiness systems, todayannounced that it has signed an agreement with AMAG Pharmaceuticals, Inc.to deliver its industry-centric CRM solution known as StayinFront Pharma.AMAG will deploy StayinFront's flagship product, StayinFront Pharma 10, forits U.S. field sales...
AMAG Pharmaceuticals, Inc. to Webcast Upcoming Analyst and Investor Meeting
CAMBRIDGE, Mass. -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will webcast its Analyst and Investor meeting taking place on June 6, 2008 in New York City beginning at 8:00 am ET. At the meeting, the Company intends to discuss the ferumoxytol development program, the chronic kidney disease market...
AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
SHENYANG, China, May 28 /Xinhua-PRNewswire-FirstCall/ -- AMAG Pharmaceuticals, Inc. and 3SBio, Inc. , a leading Chinese biotechnology company, today announced the signing of a development and commercialization agreement for ferumoxytol, an intravenous iron replacement therapeutic agent being developed to treat iron deficiency anemia in chronic kidney disease CKD patients....
AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
CAMBRIDGE, Mass. -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and 3SBio, Inc. (NASDAQ: SSRX), a leading Chinese biotechnology company, today announced the signing of a development and commercialization agreement for ferumoxytol, an intravenous iron replacement therapeutic agent being developed to treat iron deficiency anemia in chronic kidney disease CKD patients. ...
AMAG Pharmaceuticals, Inc. Announces Appointment of Robert M. Brenner, M.D. as Senior Vice President of Medical Affairs
CAMBRIDGE, Mass. -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the appointment of Robert M. Brenner, M.D. to the position of Senior Vice President of Medical Affairs. Dr. Brenner brings nearly a decade of clinical development and medical affairs experience to the Company, having served most recently as Executive Director...
AMAG Pharmaceuticals, Inc. to Present at the 2008 Citi Global Healthcare Conference
CAMBRIDGE, Mass. -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Louis Brenner, MD, Senior Vice President, will present an overview of the Company at the 2008 Citi Global Healthcare Conference on Thursday, May 22 at 11:30 a.m. ET. The conference is being held May 21-22, 2008 in New York...
AMAG Pharmaceuticals, Inc. Added to NASDAQ Biotech Index
CAMBRIDGE, Mass. -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) a biotechnology company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today announced that it has been selected...
AMAG Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
CAMBRIDGE, Mass. -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced Louis Brenner MD, Senior Vice President and David Arkowitz, Chief Financial Officer and Chief Business Officer, will present an overview of the Company at the Morgan Stanley Global Healthcare Unplugged Conference on Thursday, May 1 at 8:40 a.m. ET. The...
AMAG Pharmaceuticals, Inc. Reports Financial Results for the Quarter Ended March 31, 2008
CAMBRIDGE, Mass. -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the...
AMAG Pharmaceuticals, Inc. to Host Conference Call on April 25, 2008 to Discuss Financial Results for the Quarter Ended March 31, 2008
CAMBRIDGE, Mass. -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2008 before the U.S. financial markets open on Friday, April 25, 2008. The announcement will be followed by a conference call at 8:00 a.m. ET during which...
BellwetherReport.com Free Analyst Review for AMAG Pharmaceuticals, Spirit AeroSystems Holdings, Iomega Corp and Circuit City
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased research on the companiesmentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have scheduled interviews with a number of the...
AMAG Pharmaceuticals, Inc. to Present Additional Positive Results from Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement Therapeutic at National Kidney Foundation Spring Clinical Meetings
CAMBRIDGE, Mass. -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, announced that two posters on...
- Next »
- page 1 of 1
- « Previous
Sort byClose
View Related Content by Tag Close
- Incorporated: 1981
- CEO: Dr. Brian J. G. Pereira
- Employees: 42
AMAG Pharmaceuticals is engaged in the development and commercialization of its proprietary nanoparticle technology for use in therapeutic iron compounds to treat anemia as well as imaging agents to aid in the diagnosis of cancer and cardiovascular disease. At Sep 30 2006, Co. had two approved products, Feridex I.V.®, its liver contrast agent; and GastroMARK®, its oral contrast agent. Co. also had two product candidates: ferumoxytol, for use as an intravenous iron replacement therapeutic in chronic kidney disease patients; and Combidex®, a molecular imaging agent designed to aid in the differentiation of cancerous from normal lymph nodes.
Key Competitors
AMAG Pharmaceuticals Inc. Company Info
Board of Directors
Mr. Mark Skaletsky
Chairman
Dr. Joseph V. Bonventre M.D., Ph
Dr. Michael D. Loberg Ph.D.
Mr. Michael Narachi
Dr. Brian J. G. Pereira
Mr. Davey S. Scoon
Mr. Ron Zwanziger
Contact Information
125 CambridgePark Drive
6th Floor
Cambridge, MA
http://www.advancedmagnetics.com
617 498-3300